On October 30, 2015, the Department of Justice announced that 457 hospitals in 43 states had agreed to settle, for more than $250 million, False Claims Act allegations related to cardiac devices that were implanted in Medicare patients in violation of Medicare coverage requirements. The Department of Justice negotiated 70 separate settlements with the hospital systems,
Contractors PAE Government Services Inc. and RM Asia (HK) Limited, tasked with vehicle maintenance capabilities and training services for the Afghanistan National Army, will pay $1.45 million to resolve false claims to the Government. Former PAE employee and qui tam Relator Steven D. Walker, along with the government, alleged that former managers for PAE and RM Asia engaged in a bid-rigging scheme that funneled government paid subcontracts to companies owned by the former managers and their family members by using confidential bid information to beat out competitors.
On August 6, 2015, the United States filed its Complaint in Intervention against Latonya (Tonya) Mallory, BlueWave Healthcare Consultants, Inc., Floyd Calhoun (Cal) Dent and Robert Bradford (Brad) Johnson for their part in a Medicare and Tricare fraud scheme involving three laboratories, including Health Diagnostics Laboratories, Inc., of Richmond, VA and Singulex,
VMware Inc., a manufacturer of computer visualization software, and Carahsoft Technology Corporation, a distributor of information technology, will be paying $75.5 million to settle claims that they made misrepresentations that allowed them to overcharge the government for VMware’s products and services. Under the United States General Services Administration’s (“GSA”) Multiple Award Schedule Program,
On May 19, 2015, Vermont Governor Peter Shumlin signed into law a state false claims act that largely mirrors the federal False Claims Act, including the ability of a qui tam relator to bring an action on behalf of the state. Whistleblowers will be enticed to report fraud in companies doing work for state and local governments through the new Vermont False Claims Act,
Last Tuesday, the United States Supreme Court issued its long-awaited ruling in United States ex rel. Carter v. KBR, Inc. The case dealt with two significant procedural issues related to the False Claims Act (“FCA”): (1) whether the tolling provisions of the Wartime Suspension of Limitations Act (“WSLA”) applied to civil as well as criminal claims;
On Tuesday, in United States ex rel. Nevyas v. Allergan, Inc., an Eastern District of Pennsylvania district court denied pharmaceutical giant Allergan’s motion to dismiss False Claims Act (“FCA”) allegations brought against it by Relator eye doctors in the Philadelphia area. In so doing, the Court rejected Allergan’s novel argument that,
On May 14, 2015, PharMerica Corp. agreed to pay $31.5 million to resolve a False Claims Act and Controlled Substances Act lawsuit alleging that the company had dispensed Schedule II controlled drugs without valid prescriptions and then billed Medicare for the improperly dispensed drugs.
PharMerica, a long-term care pharmacy that dispenses medications to residents of long-term care facilities,
The United States Department of Justice (“DOJ”) recently announced that PharMerica Corp. will pay $31.5 million, including more than $4 million to a whistleblower, to settle alleged violations of the Controlled Substances Act (“CSA”) and False Claims Act (“FCA”) related to the company’s improper dispensing of narcotics and submission of false claims to Medicare Part D.
Bills signed by Governor Larry Hogan, Speaker of the House Michael Busch and Senate President Mike Miller include, expanding the Maryland False Claims Act protecting whistleblowers.
Whistleblowers will be enticed to report fraud in companies doing work for state and local governments through the new Maryland False Claims act,
If you are aware of any person, corporation or entity that you think may be violating the Federal False Claims Act or a State False Claims Act, contact us today.